What is the optimal duration of adjuvant therapy in colon cancer?

Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702.

Journal of the National Cancer Institute·2026

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

Cancer letters·2026

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Oncogene·2026

CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer.

BMJ oncology·2026

CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.

Journal for immunotherapy of cancer·2026

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.

NPJ precision oncology·2026

Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.

Clinical advances in hematology & oncology : H&O·2026

Neoadjuvant therapies in high-risk localized prostate cancer: past, present, and future.

Clinical advances in hematology & oncology : H&O·2026

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

Clinical advances in hematology & oncology : H&O·2026

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026

The effects of combined aerobic and resistance exercise on metabolic blood biomarkers and quality of life in patients with breast cancer: a systematic review meta-analysis.

Frontiers in oncology·2026

New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapy.

Frontiers in allergy·2026

Case Report: Can this 90-year-old patient with cT4N3M0 NSCLC have concurrent chemoradiation for cure? Learning from a representive case.

Frontiers in oncology·2026

Conjunctival reactive cutaneous capillary endothelial proliferation induced by camrelizumab in an esophageal cancer patient: a case report and literature review.

Frontiers in oncology·2026

Oxygen-Gradient-Responsive Photosensitizing Gadolinium Phthalocyaninate for Self-Adaptive Type II/I Photodynamic Therapy Toward Heterogeneous Tumor Suppression.

Small (Weinheim an der Bergstrasse, Germany)·2026

An Immunogenic Cell Death-Enhanced Self-Assembled Nanoparticle-Composite Hydrogel for Postoperative Local Immunotherapy of Melanoma.

Omics : a journal of integrative biology·2026

Related Experiment Videos

What is the optimal duration of adjuvant therapy in colon cancer?

Related Concept Videos

Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702.

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer.

CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.

Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.

Neoadjuvant therapies in high-risk localized prostate cancer: past, present, and future.

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

The effects of combined aerobic and resistance exercise on metabolic blood biomarkers and quality of life in patients with breast cancer: a systematic review meta-analysis.

New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapy.

Case Report: Can this 90-year-old patient with cT4N3M0 NSCLC have concurrent chemoradiation for cure? Learning from a representive case.

Conjunctival reactive cutaneous capillary endothelial proliferation induced by camrelizumab in an esophageal cancer patient: a case report and literature review.

Oxygen-Gradient-Responsive Photosensitizing Gadolinium Phthalocyaninate for Self-Adaptive Type II/I Photodynamic Therapy Toward Heterogeneous Tumor Suppression.

An Immunogenic Cell Death-Enhanced Self-Assembled Nanoparticle-Composite Hydrogel for Postoperative Local Immunotherapy of Melanoma.

Related Experiment Videos

What is the optimal duration of adjuvant therapy in colon cancer?

Related Concept Videos

Related Articles